Accuracy of wavefront aberrometry in cataract patients

Article

Loss of optical media transperency reduces accuracy in clinical practice

Wavefront aberrometry (WA) offers promising applications in ophthalmology and can provide valuable information in previously underresearched conditions including hyperopia and cataract-related reduced visual acuity (VA). In clinical settings, WA is frequently used to assess patients presenting for refractive surgery, and previous studies have demonstrated a high level of accuracy of WA measurements in comparison to those of manifest refraction (MR) and autorefraction. However, the subjects of these studies have primarily been young, myopic and well-sighted patients, while in clinical practice the majority of patients presenting for cataract surgery are of advanced age, with ametropia and reduced VA.

As a patient's VA can be affected when WA is used as a basis for surgical treatment of pathological conditions (particularly if the measurements are less accurate in specific patient populations), Dr Stephan Linke, Dr Jan Hülle (University Medical Center HamburgEppendorf, Germany) and colleagues decided to conduct a study to evaluate the accuracy of WA in comparison to MR in an older population awaiting cataract surgery.1 The trial was intended to help the team determine if previous study results can be replicated in clinical practice and to establish which factors, if any, affect the accuracy of the refractive values as measured by WA.

Assessing the eyes

"We had anticipated that WA would measure the same refractive values as MR, but that potential measurement differences between the devices would be explained either by the refractive state - hyperopia versus myopia - or by age. We also thought that the only impact of cataract on the results would be that more progressed forms of cataract would lead to more exaggerated differences between measurements taken on the separate devices," explained Dr Hülle. "However, some of the results we actually achieved were surprising, and were in fact contrary to previously published conclusions."

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.